Summary
Severe narcosis occurred in a patient with hypoparathyroidism given therapeutic doses of codeine phosphate.
Case report
A 50-year-old woman had suffered from rheumatoid arthritis for many years. Removal of a goitre in 1975 revealed amyloid which was also found in a renal biopsy later that year when chronic renal failure was diagnosed. Also in 1975 she developed troublesome diarrhoea and was given codeine phosphate up (Findlay, Butz and Welch, 1977) .
Three days later codeine and norcodeine were undetectable and no morphine was detected on either occasion. Since then she has remained well, again taking 1,m-hydroxycholecalciferol.
Discussion
The reversal of narcosis by naloxone indicates that codeine or an endogenous opiate-like peptide had caused the clinical state. A number of mechanisms might explain an acquired intolerance to therapeutic plasma concentrations of codeine. The contribution of acidosis cannot be discounted simply because of lack of effect of i.v. bicarbonate but no evidence exists directly to link pH to opiate action. An interaction with hypocalcaemia is more likely. Tests on animals show that depletion of brain calcium can increase the analgesic effect of morphine. Intraventricular administration of calcium ion can antagonize the analgesic effect of morphine but the effect of peripheral injections of calcium is much less, possibly because morphine inhibits calcium uptake into the brain (Snyder, 1977) . This might explain the lack of effect of i.v. calcium in the present patient.
Changes in production or release of encephalins within the brain probably account for many features of exogenous opiate administration (Kaneto, 1971) .
As calcium has been implicated as a mediator of release of several other polypeptides, an interaction at this level is certainly possible.
It will be noted that the plasma levels of codeine, although within the therapeutic range, are inappropriately high in relation to the time since the last recorded dose. There are several possible explanations for this finding. Firstly, although detailed data on narcotic metabolism in renal failure are lacking there is quite likely to be a prolongation of plasma half-life of codeine with diminished renal function. Codeine is, however, commonly prescribed where renal function is as bad as or worse than in this patient, and unwanted effects other than constipation are rarely reported. Secondly, it is possible that larger or more frequent doses of codeine than those recorded on the prescription sheet were actually given. Although the patient's reduced level of consciousness was actually the main factor in preventing further doses being given it is also possible that the final dose given was closer than had been thought to the time of plasma sampling and that the dose had not been charted correctly. Although these latter hypotheses would explain the inappropriately high plasma concentration they cannot be tested and appear rather unlikely.
It is suggested that there may be unexpected problems in using codeine and other narcotic analgesics in hypocalcaemic patients. 
